Clinical Trial Detail

NCT ID NCT03708328
Title A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

Advanced Solid Tumor

lung small cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

RO7121661

Age Groups: adult senior

Additional content available in CKB BOOST